A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).
- Published In:
- Expert opinion on therapeutic patents, 28(9), 665-678 (2018)
- Authors:
- Shaabani, Shabnam, Huizinga, Harmen P S, Butera, Roberto, Kouchi, Ariana, Guzik, Katarzyna, Magiera-Mularz, Katarzyna, Holak, Tad A, Dömling, Alexander
- Database ID:
- RPEP-03893
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03893APA
Shaabani, Shabnam; Huizinga, Harmen P S; Butera, Roberto; Kouchi, Ariana; Guzik, Katarzyna; Magiera-Mularz, Katarzyna; Holak, Tad A; Dömling, Alexander. (2018). A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).. Expert opinion on therapeutic patents, 28(9), 665-678. https://doi.org/10.1080/13543776.2018.1512706
MLA
Shaabani, Shabnam, et al. "A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).." Expert opinion on therapeutic patents, 2018. https://doi.org/10.1080/13543776.2018.1512706
RethinkPeptides
RethinkPeptides Research Database. "A patent review on PD-1/PD-L1 antagonists: small molecules, ..." RPEP-03893. Retrieved from https://rethinkpeptides.com/research/shaabani-2018-a-patent-review-on
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.